PIWIL3 and neoplasm: Indeed, PIWIL3 and/or PIWIL4 silencing overcame Gemcitabine resistance of the non-tumor cell line (p < 0.001), and significantly increased the other treatment effects (p = 0.003 for Nab-Paclitaxel; p = 0.001 for Gemcitabine + Nab-Paclitaxel) (Figure 4C).